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Abstract In a previous study [Wang et al. (1996) Nat. Med. 2,
871^875], Wang et al. found (i) that abnormally hyperphos-
phorylated tau (AD P-tau) isolated from Alzheimer’s disease
(AD) brain as paired helical filaments (PHF)-tau and as
cytosolic AD P-tau but not tau from normal brain were stained
by lectins, and (ii) that on in vitro deglycosylation the PHF
untwisted into sheets of thin straight filaments, suggesting that
tau only in AD brains is glycosylated. To elucidate the primary
structure of N-glycans, we comparatively analyzed the N-glycan
structures obtained from PHF-tau and AD P-tau. More than
half of N-glycans found in PHF-tau and AD P-tau were
different. High mannose-type sugar chains and truncated N-
glycans were found in both taus in addition to a small amount of
sialylated bi- and triantennary sugar chains. More truncated
glycans were richer in PHF-tau than AD P-tau. This enrichment
of more truncated glycans in PHF might be involved in
promoting the assembly and or stabilizing the pathological
fibrils in AD. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly population. Although the pathogenesis
of the disease is not yet understood, AD is characterized by
the presence of two histopathological hallmark brain lesions,
extracellular deposits of L-amyloid in neuritic plaques and
intracellular neuro¢brillary tangles. AD is characterized by a
speci¢c type of neuronal degeneration (called ‘neuro¢brillary
degeneration’), in which the neuronal cytoskeleton is progres-
sively disrupted and displaced by the appearance of bundles of
paired helical ¢laments (PHFs), the neuro¢brillary tangles.
Neurons with neuro¢brillary tangles lack microtubules, and
microtubule assembly from AD brain cytosol is not observed
[1]. PHFs are comprised mainly of the microtubule-associated
protein tau in an abnormally hyperphosphorylated state [2^4].
Tau in PHF (PHF-tau) is di¡erent from that in normal neu-
rons. In AD brain, in addition to PHF, there is a cytosolic
pool of the abnormally hyperphosphorylated tau (AD P-tau)
as amorphous aggregates [5]. Compared with normal tau,
which contains two to three phosphate groups, the AD P-
tau contains 5^9 mol of phosphate per mol of the protein
[5]. This pool of abnormal tau, which is soluble in physiolog-
ical bu¡er conditions, disrupts microtubules and inhibits their
assembly in vitro [6^9]. Evidence from several studies has
indicated that the hyperphosphorylation of tau is responsible
for its loss of biological activity and its resistance to proteo-
lytic degradation, and probably plays a key role in neuro¢-
brillary degeneration in AD.
In a previous study [10], we found that PHF-tau and AD
P-tau but not normal tau were stained by lectins and that on
in vitro deglycosylation the PHF untwisted into thick straight
¢laments, suggesting that tau in only AD brain was glycosy-
lated. Deglycosylation plus dephosphorylation, but not degly-
cosylation alone, of AD P-tau and tau from PHF tangles
restored their microtubule polymerization activity [8,9]. The
glycosylation of PHF in AD brain was also con¢rmed immu-
nocytochemically by lectin binding [11]. Thus, glycosylation
appeared to be responsible for the maintenance of the PHF
structure. To elucidate the relationship between glycosylation
of tau and the pathogenesis of AD, information on the exact
carbohydrate structures of the pathological tau is required. In
this study, we comparatively analyzed the primary structure of
N-glycans of PHF-tau and AD P-tau.
2. Materials and methods
2.1. Enzymes
Arthrobacter ureafaciens sialidase and bovine epididymal K-fucosi-
dase were purchased from Nacalai Tesque (Kyoto, Japan), and from
Sigma Chemicals Co. (St. Louis, MO, USA), respectively. Diplococcal
L-galactosidase and L-N-acetylhexosaminidase were purchased from
Roche Molecular Biochemicals (Mannheim, Germany). Jack bean L-
N-acetylhexosaminidase and K-mannosidase, and snail L-mannosidase
were purchased from Seikagaku Co. (Tokyo, Japan). Aspergillus saitoi
K-mannosidase I was puri¢ed according to Amano and Kobata [12].
2.2. Puri¢cation of normal tau, AD P-tau and PHF-tau
Histopathologically con¢rmed AD brains obtained between 3 and
5 h post-mortem and stored at 375‡C were used. The human tissue
was obtained from the Brain Resource Center McLean Hospital, Bel-
mont, MA, USA. AD P-tau was isolated by the method of Ko«pke et
al. [5]. Bovine tau was isolated as described [4] for acid-soluble tau
(tau isolated from a HClO4 brain extract) and chromatography on a
phosphocellulose (cellulose phosphate P11, Whatman) column.
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AD P-tau was prepared from the 27 000Ug to 200 000Ug fraction
of the AD brain homogenate. This fraction contains soluble abnor-
mally phosphorylated tau (AD P-tau) and individual PHFs. For the
isolation of AD P-tau from PHFs, the above fraction was extracted in
8 M urea, followed by acid precipitation, chromatography on a phos-
phocellulose column and dialysis against MES bu¡er as described
previously [5]. PHF-tau was isolated from AD brains as described
previously [13]. Brie£y, cerebral cortex, cleaned free of white matter
and meninges, was fractionated by a combination of sieving through
nylon bolting cloth, treatment with 2% sodium dodecyl sulfate (SDS),
and by discontinuous sucrose density gradients and glass beads chro-
matography. Protein was estimated as previously described [14]. The
puri¢ed taus thus obtained gave several polypeptides on SDS^PAGE,
and all were reactive on Western blots with the tau polyclonal and
monoclonal antibodies (Fig. 1). Rabbit antibody 92e [7] and mono-
clonal antibody Tau-1 (after alkaline phosphatase treatment of the
blots; [3]) recognize total tau.
2.3. 2-Aminobenzamide (2AB) derivatization of
N-glycans released from tau
Three puri¢ed taus (bovine tau, 165 Wg; PHF-tau, 120 Wg; AD
P-tau, 150 Wg) were thoroughly dried over P2O5 in vacuo and sub-
jected to hydrazinolysis at 100‡C for 9 h. Liberated oligosaccharides
were N-acetylated and puri¢ed as described previously [15]. This pro-
cedure releases the N-linked sugar chains of glycoproteins quantita-
tively as oligosaccharides.
The total N-glycans obtained above were labeled with 2AB as de-
scribed previously [16]. To detect the 2AB-labeled oligosaccharides,
£uorescence emission was monitored at 420 nm with excitation at 330
nm. Since any 2AB-labeled oligosaccharides could not be obtained
from bovine tau, further study was not performed.
2.4. Oligosaccharides
A total of 10 oligosaccharides were obtained (Table 1). G2, G2F
and GN2FB were obtained from lipocalin-type prostaglandin D syn-
thase puri¢ed from human urine by hydrazinolysis and derivatized by
2AB as described above [16]. G3 was obtained from fetuin [17], and
M9 and M5 were obtained from human IgM [18], respectively. M3
and M3F were obtained by digestion of G2 and G2F with a mixture
of diplococcal L-galactosidase and L-N-acetylhexosaminidase, respec-
tively. M1 and M1F were obtained by digestion of M3 and M3F with
jack bean K-mannosidase, respectively.
2.5. Analytical methods
Column chromatographies and other experimental procedures used
in this work have been described in the previous papers [16]. Exogly-
cosidase digestion was performed according to the methods described
previously [16].
Molecular mass of the 2AB-labeled oligosaccharides was deter-
mined by matrix-assisted laser desorption ionization Fourier trans-
form mass spectrometry (MALDI-FTMS). 2,5-Dihydroxybenzoic
acid, which was purchased from Sigma Aldrich, was used as the
matrix. It was dissolved to a concentration of 10 mg/ml of 30% aque-
ous ethanol. Dried 2AB-labeled oligosaccharide was dissolved in the
matrix solution (2 pmol/Wl). Aliquots of the resulting mixtures (5 Wl)
were placed onto probe tips and dried at room temperature. The
molecular masses of the oligosaccharides were determined using a
BioAPEX 47e (4.7-T, Bruker Daltonics GmbH, Bremen, Germany)
FTMS.
3. Results
3.1. Fractionation of oligosaccharides by
anion-exchange column chromatography
The 2AB-labeled oligosaccharide mixtures obtained from
AD P-tau and PHF-tau were separated into a neutral (N)
and acidic fraction (A) by anion-exchange chromatography
on a Mono Q HR5/5 column (Fig. 2). By exhaustive A. urea-
faciens sialidase digestion, a part of acidic fraction was con-
verted into neutral oligosaccharides, indicating that sialic
acids are included as the acidic residues in these oligosaccha-
rides. The neutral oligosaccharide fraction obtained from frac-
tion A was named fraction AN. Components not digested by
sialidase may contain other anionic residues such as sulfated
sugars and uronic acids, although no further analysis was
performed due to the limited amounts of sample. Therefore,
fractions N and AN were subjected to structural analysis as
below.
3.2. Fractionation of the neutral oligosaccharides by normal
phase high performance liquid chromatography (HPLC)
When fractions N and AN from AD P-tau and PHF-tau
were subjected to normal phase HPLC, ¢nally 12 peaks were
obtained as shown in Fig. 3. It should be noted that peaks d,
e, f, g and l were only detected in AD P-tau and that peaks h
and i were only in PHF-tau. Remaining ¢ve peaks were found
in both samples. In order to determine the anomeric con¢g-
uration and monosaccharide sequences of each component in
Fig. 3, they were subjected to sequential exoglycosidase diges-
tion, and the reaction products at each step were analyzed by
normal phase HPLC (Fig. 4). Schematic diagram of sequential
glycosidase digestions is shown in Fig. 5.
Information on the molecular weights of these components
is helpful for the interpretation of the results obtained by
HPLC as above and sequential exoglycosidase digestion as
will be described later. Due to the limited amounts of sample,
the molecular weights of component a and component b were
determined by MALDI-FTMS. The observed [M+Na] ion
Fig. 1. SDS^PAGE and Western blots of puri¢ed PHF-tau and AD
P-tau used for the analysis of the primary structure of N-glycans.
AD P-tau, and PHF-tau (8 Wg/lane for staining; and 4 Wg/lane for
Western blots) were subjected to 7.5^15%, 5^15% SDS^PAGE, re-
spectively, transferred to a PVDF membrane, and either stained
with dye or immunostained with a polyclonal antibody 92e to tau
(in the case of PHF-tau) or with tau monoclonal antibody Tau-1 to
the alkaline phosphatase-treated membrane (in the case of AD
P-tau) as described previously [8]; the staining of PHF-tau and AD
P-tau with lectins was shown previously [10]. CB, Coomassie blue
staining; II, India ink staining; WB, Western blots. Molecular
weight markers were prestained phosphorylase b (97 kDa), bovine
serum albumin (70.5 kDa), ovalbumin (44.2 kDa) and carbonic an-
hydrase (27.8 kDa) from Gibco BRL/Life Technologies.
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peaks of component a and component b were at m/z 1377.6
and 1808.7, respectively. The observed molecular mass values
were consistent with those expected: 2AB-labeled ¢ve man-
nose-type sugar chains (Hex5WHexNAcWHexNAc-2AB, 1377),
and 2AB-labeled fucosylated bisected non-galactosyl-bianten-
nary ones (Hex3WHexNAc4WDeoxyHexWHexNAc-2AB, 1808).
3.3. Structural studies
3.3.1. Components j and k. As shown in Fig. 3, compo-
nent j and component k were eluted at the same positions as
authentic G2 (7.3 glucose units (gu)) and G2F (7.9 gu) on
normal phase HPLC, respectively. These results suggested
that component j and component k are a complex-type non-
fucosylated and fucosylated biantennary sugar chains, respec-
tively. In order to con¢rm these ¢ndings, the component j and
component k were subjected to sequential exoglycosidase di-
gestion.
When component j was incubated with diplococcal L-galac-
tosidase, which cleaves the GalL1C4GlcNAc linkage only
[19], two galactose residues were removed completely from
Table 1
Structures of authentic oligosaccharides used in this study
FEBS 24848 4-5-01
Y. Sato et al./FEBS Letters 496 (2001) 152^160154
the component j (Fig. 4A). When the component in Fig. 4A
was incubated with diplococcal L-N-acetylhexosaminidase,
which cleaves the GlcNAcL1C2Man linkage only [20], it
was converted to a component with the same mobility as
authentic M3 (4.5 gu) with the release of two N-acetylglucos-
amine residues (Fig. 4B). The component in Fig. 4B was con-
¢rmed by sequential digestion with jack bean K-mannosidase,
L-mannosidase, and jack bean L-N-acetylhexosaminidase.
On the other hand, sequential exoglycosidase digestion of
component k gave a series of products which were larger in
size by approximately 0.5 gu than those in the case of com-
ponent j (dotted lines in Fig. 4A,B, respectively). The dotted-
line component in Fig. 4B, which was eluted at the same
position as authentic M3F (5.0 gu) was con¢rmed by sequen-
tial digestion with jack bean K-mannosidase followed by L-
mannosidase, jack bean L-N-acetylhexosaminidase, and K-fu-
cosidase. Based on these results, the proposed structures of
Fig. 3. Normal phase HPLC of components in fractions N and AN
from Fig. 2. (A) Fraction N of AD P-tau; (B) fraction N of PHF-
tau; (C) fraction AN of AD P-tau; (D) fraction AN of PHF-tau.
Each fraction was applied to a GlycoSep-N column and eluted in a
250 mM ammonium acetate^acetonitrile gradient solvent system at
a £ow rate of 1 ml/min at 30‡C. The 250 mM acetate^acetonitrile
ratio was changed linearly from 20:80 to 53:47 (v/v) during 132
min. Peaks were assigned gu values by comparison with the 2AB-la-
beled glucose oligomer ladder shown at the top of A. The open tri-
angles indicate the elution positions of the 2AB-labeled authentic
oligosaccharide standard, I, M3F; II, M5; III, M9; IV, G2;
V, G2F; VI, G3. Asterisks indicate contaminating materials.
Fig. 2. Anion-exchange column chromatography of 2AB-labeled
N-glycans from AD P-tau and PHF-tau. 2AB-labeled oligosaccha-
rides were subject to HPLC using a Mono Q HR5/5 column. After
elution of the neutral oligosaccharides with 10 ml of water, the
acidic oligosaccharides were eluted with a 0^600 mM gradient of
ammonium acetate, pH 4.0, at a £ow rate of 1 ml/min at room tem-
perature (dotted line). (A) Oligosaccharides from AD P-tau; (B) fol-
lowing de-sialylation of fraction A in (A) by digestion with A. urea-
faciens sialidase; (C) oligosaccharides from PHF-tau; (D) following
de-sialylation of fraction A in (C) by the same enzymatic treatment.
N, neutral glycans; A, acidic glycans; AN, acidic neutral glycans.
To detect the 2AB-labeled oligosaccharides, £uorescence emission
was monitored at 420 nm with excitation at 330 nm.
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component j and component k were concluded to be shown in
Table 2.
3.3.2. Component l. On normal phase HPLC, the compo-
nent l migrated to the same position as authentic G3 (Fig.
3C). The component l released three galactose residues by
diplococcal L-galactosidase digestion (Fig. 4C) and three N-
acetylglucosamine residues by sequential jack bean L-N-ace-
tylhexosaminidase digestion (Fig. 4D). The component at this
stage moved to the same position as authentic M3 (4.5 gu).
These results indicated that it is a non-fucosylated trianten-
nary oligosaccharide. When digested with diplococcal L-N-
acetylhexosaminidase, the component in Fig. 4C released
two N-acetylglucosamine residues (Fig. 4D, dotted line). The
diplococcal enzyme can release two underlined N-acetylglu-
cosamine residues from the following oligosaccharides [20] :
Based on the results, the structure of component l was
proposed to be shown in Table 2.
3.3.3. Components a, c, e, f, and g. When components in
fraction N (underlined in Fig. 3A) were incubated with A.
saitoi K-mannosidase I, which cleaves the ManK1C2Man
linkage only [21], components c, e, f, and g were converted
to component a, which was eluted at the same position as
authentic M5, indicating that only these four components
contain ManK1C2Man groups (Fig. 4E). By comparison of
the mobilities of the peaks before and after the enzymatic
digestion, it was concluded that components c, e, f, and g
have one, two, three, and four ManK1C2 residues linked to
component a, respectively. However, components b and d
were resistant to this enzymatic digestion (Fig. 4E). While
structural study of component b will be described later, de-
tailed structural information of component d could not be
obtained due to the limited amounts of sample. It should be
noted, however, that component d was susceptible to K-fuco-
sidase and jack bean L-N-acetylhexosaminidase digestions.
Component a which showed the same mobility as authentic
Fig. 4. Sequential glycosidase digestion of each component fractionated by normal phase HPLC. (A) Component j (solid line) and component
k (dotted line) from Fig. 3 after digestion with diplococcal L-galactosidase; (B) the solid-line and dotted-line components from (A) after diges-
tion with diplococcal L-N-acetylhexosaminidase; (C) component l from Fig. 3D after digestion with diplococcal L-galactosidase; (D) the com-
ponent from (C) after digestion with jack bean L-N-acetylhexosaminidase (solid line) and with diplococcal L-N-acetylhexosaminidase (dotted
line); (E) the components underlined in Fig. 3A after digestion with A. saitoi K-mannosidase I; (F) component b from (E) after digestion with
jack bean L-N-acetylhexosaminidase (solid line) or with diplococcal L-N-acetylhexosaminidase (dotted line); (G) peak h in Fig. 3B after diges-
tion with jack bean K-mannosidase; (H) component i from Fig. 3B after digestion with diplococcal L-N-acetylhexosaminidase. The open trian-
gles indicate the elution positions of the 2AB-labeled authentic oligosaccharide standard, I, M3F; II, M3; III, M5; IV, GN2FB; V, M1F;
VI, M1. The solid triangles show the position of the 2AB-labeled glucose oligomers as in Fig. 3.
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M5 was con¢rmed by sequential digestion with jack bean
K-mannosidase, L-mannosidase, and jack bean L-N-acetylhex-
osaminidase. On the other hand, only component c in fraction
N of PHF-tau (Fig. 3B) was digestible by A. saitoi K-manno-
sidase I, releasing a single mannose residue (data not shown).
Therefore, components a, c, e, f, and g are a series of high
mannose-type sugar chains as shown in Table 2.
3.3.4. Component b. As shown in Fig. 4E, A. saitoi
K-mannosidase I resistant component b was eluted at the
same position as authentic GN2FB (6.5 gu), suggesting that
these are complex-type fucosylated bisected non-galactosyl-
biantennary oligosaccharide.
To con¢rm the ¢ndings, component b was subjected to
sequential digestion. Component b released three N-acetylglu-
cosamine residues by jack bean L-N-acetylhexosaminidase di-
gestion and co-eluted with authentic standard M3F (5.0 gu)
(Fig. 4F). On the other hand, the component b released only
one N-acetylglucosamine residue by diplococcal L-N-acetyl-
hexosaminidase digestion (6.0 gu) (Fig. 4F, dotted line).
These results indicated that the structure of the component
b was GlcNAcL1C2ManK1C6(GlcNAcL1C2ManK1C3)-
(GlcNAcL1C4)ManL1C4GlcNAcL1C4(FucK1C6)GlcNAc-
2AB. As reported previously [20], diplococcal L-N-acetylhex-
osaminidase cleaves only the underlined L-N-acetylglucos-
amine residue from the above oligosaccharide. Based on these
results together with the molecular mass data, the proposed
structure of component b was summarized in Table 2.
3.3.5. Components h and i. As shown in Fig. 3B, compo-
nent h seemed to be eluted as a single peak on normal phase
HPLC. However, when this peak was incubated with jack
bean K-mannosidase, two components, h1 and h2, appeared
(Fig. 4G). Component h1 was co-eluted at the same position
as authentic M1F (3.3 gu) and component h2 was as authentic
M1 (2.6 gu), respectively. By comparison of the mobilities of
the peaks before and after the enzymatic digestion, it was
concluded that peak h was a mixture of a component having
two K-mannose residues linked to component h1 and another
component having three K-mannose residues linked to com-
ponent h2, respectively. The structure of h2 was con¢rmed by
sequential digestion with snail L-mannosidase followed by
jack bean L-N-acetylhexosaminidase, and that of h1 was
also done by the same enzymatic digestion followed by
K-fucosidase digestion. Based on these results, the proposed
structures of components in peak h are shown in Table 2.
Component i (5.8 gu) released only one N-acetylglucos-
amine residue by diplococcal L-N-acetylhexosaminidase diges-
tion (5.0 gu) (Fig. 4H). The results of sequential exoglycosi-
dase digestions of the component in Fig. 4H were the same as
authentic M3F. Therefore, component i was fucosylated
mono N-acetylglucosaminylated trimannosyl core, as shown
in Table 2.
4. Discussion
In a previous study, Wang et al. [10] found that normal tau
was not stained by lectin binding on Western blots, suggesting
that the glycosylation of tau is not a normal physiological
modi¢cation. The absence of N-glycans on normal tau is con-
¢rmed in the present study by a chemical method, hydrazi-
nolysis, which is well known to release the N-glycans of gly-
coproteins quantitatively as oligosaccharides [15]. This ¢nding
is also consistent with a previous study which showed that
bovine tau was not N-glycosylated on the basis of the suscep-
tibility to peptide: N-glycanase (PNGase) [22]. On the other
hand, the recovery of N-linked oligosaccharides from PHF-
tau and AD P-tau by hydrazinolysis con¢rmed the glycosyla-
tion of PHF-tau and AD P-tau shown previously by lectin
binding on Western blots [10] and immunocytochemically by
lectin binding in AD brain [11].
One of ‘brain-type’ N-glycan structures [23^26], truncated,
fucosylated, bisected biantennary sugar chain (component b in
Table 2), was found in both PHF-tau and AD P-tau. A series
of high mannose-type sugar chains were also detected in both
taus, while compositional di¡erence was found. The presence
of high mannose-type sugar chains is consistent with a pre-
vious study in which AD P-tau and PHF-tau were positively
stained by a lectin, Galanthus nivalis agglutinin (GNA) [10]. It
is known that GNA is a mannose binding lectin and exhibits
high a⁄nity for the branched trisaccharide Man-
K1C6(ManK1C3)Man [27]. When compared between AD
P-tau and PHF-tau, the small glycans were richer in PHF-
tau than in AD P-tau; e.g. components h and i were found
only in PHF-tau. AD P-tau is probably a precursor form of
PHF tau [5]. Tangles are long lived as compared to AD P-tau.
The enrichment of small glycans in PHF probably represents
a more advanced stage of processing of glycans in these long
lived structures. Since the glycan moiety of a glycoprotein
modi¢es the properties of the protein [28], subtle structural
change of N-glycan may induce conformational change. The
changes in the glycans composition from AD P-tau to PHF-
tau might reduce structural stability to PHF.
Fig. 5. Schematic diagram of sequential exoglycosidase digestions
used to determine the structures of the N-glycans. Symbols used for
the monosaccharides units and 2AB are: a, galactose; E, N-acetyl-
glucosamine; b, mannose; O, fucose; C, 2AB. The exoglycosidases
used are: I, diplococcal L-galactosidase; II, diplococcal L-N-acetyl-
hexosaminidase; III, jack bean L-N-acetylhexosaminidase; IV, A.
saitoi K-mannosidase I; V, jack bean K-mannosidase; VI, snail
L-mannosidase; VII, bovine epididymal K-fucosidase.
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Table 2
Proposed structures and their percent molar ratios of N-glycans obtained from AD P-tau and PHF-tau
*Not detected. The percentage molar ratios of N-glycans in AD P-tau and PHF-tau were determined by £uorescence intensity.
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The appearance of N-glycosylated tau in patients with AD
may be relevant to the understanding of the pathology of this
disease. It is known that human tau has three potential N-gly-
cosylation sites (Asn167-Ala-Thr, Asn359-Ile-Thr, and Asn410-
Val-Ser; amino acids are numbered according to the longest
isoform of human brain tau [29]). Although the AD-depen-
dent mechanism by which tau becomes N-glycosylated re-
mains to be elucidated, several possibilities could be consid-
ered. The ¢rst possibility is that the intracellular localization
of tau may change in AD, resulting in production of N-gly-
cosylated species of tau due to the altered accessibility to
N-glycan processing enzymes. The addition of N-glycans in
proteins is catalyzed by an oligosaccharyl transferase (OST)
[30], whose active site is considered to be located in the lume-
nal side of the endoplasmic reticulum (ER) and the processing
enzymes acting in the latter steps are also in the lumen of the
ER and Golgi apparatus. The possibility described is sup-
ported by the fact that some of tau in AD brains was asso-
ciated with ribosomes on the rough ER [31]. Additionally, we
must also consider the possibility of abnormality of import
and export system of proteins across the membrane of the ER
[32], probably due to a membrane abnormality in AD neu-
rons. Since abnormalities of membrane phospholipids in brain
and membrane £uidity have been reported in AD [33,34], it
may a¡ect the import and export system of proteins across the
membrane of the ER. A second possibility is that the activity
of an OST might increase in aberrant neurons of AD. The
OST is thought to associate closely with translation and gen-
erally to have access only to nascent chains as they emerge
from the ribosome, resulting in co-translational N-glycosyla-
tion [30]. However, recently it has been shown that even after
completion of translation, the proteins in the lumen of the ER
are accessible to OST [35]. Such a post-translational N-glyco-
sylation has been observed in unusual circumstances such as
on small acceptor tripeptide [36], on non-glycoinsulin receptor
generated by tunicamycin treatment or by glucose depriva-
tion-readdition [37,38], and with heat-induced prompt glyco-
sylation of the chaperone protein calreticulin [39]. The phe-
nomenon of post-translational N-glycosylation likely applies
to tau protein. A third possibility is that the activity of an
uncharacterized cytosolic PNGase, which could cleave the
glycan moieties from glycoproteins [40,41], might be altered
in AD neurons. Recent studies have suggested that misfolded
proteins themselves are exported across the ER membrane to
the cytosol before degradation and that cytosolic proteasomes
are responsible for this degradation process [32]. In some
cases, it has been reported that the glycoproteins are deglyco-
sylated by the action of PNGase prior to proteolytic degra-
dation by proteasomes [42^46]. Therefore, defect of deglyco-
sylation may cause the accumulation of abnormal tau.
Although details of the mechanism of cytosolic N-glycosyla-
tion are not clear, N-glycosylation of cytosolic protein like tau
might occur due to the intracellular perturbation in AD neu-
rons.
It is noteworthy that the presence of N-glycan in the cyto-
solic region has been reported; the Na pump K subunit is a
glycoprotein with its cytosolic domain N-glycosylated [47].
Furthermore, it is of interest that these N-glycans may be
GlcNAc-terminating ones because they are galactosylated by
using galactosyltransferase, a speci¢c enzyme which attaches
galactose to terminal GlcNAc residues, although ¢ne structur-
al study should be awaited. Appearance of truncated N-gly-
cans may be relevant to the presence of many glycosidases
including sialidase and L-galactosidase in the cytosol [48,49],
although occurrence of incomplete glycan processing cannot
be eliminated.
Other post-translational modi¢cations of PHF-tau have
been reported. For example, PHF-tau is both non-enzymati-
cally glycated [50] and ubiquitinated [51,52]. Recently, an up-
regulation of O-GlcNAc in AD brains [53^55] and the pres-
ence of O-GlcNAc on tau have also been reported [22]. It is
suggested that O-GlcNAcylation is an important regulatory
modi¢cation that might have a reciprocal relationship with
phosphorylation [56]. In the present study O-linked GlcNAc
in tau was not found by the hydrazine treatment which has
been reported to result in the partial degradation of O-glycans
[57].
Understanding of the mechanism of the neuro¢brillary de-
generation is critical to devising a rational, therapeutic treat-
ment of AD. Elucidation of aberrant N-glycosylation of tau
might lead us to a greater understanding of the pathogenesis
of AD.
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